Compare Medpace Holdings Inc (MEDP) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Medpace Holdings Inc trades at $613.05 (market cap $16.82B), while YieldMax MSTR Option Income Strategy ETF trades at $15.75 (market cap $1.06B). The key difference: Medpace Holdings Inc is far larger — about 15.9× YieldMax MSTR Option Income Strategy ETF's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and YieldMax MSTR Option Income Strategy ETF for 30 Days on average.
| MEDP | MSTY | |
|---|---|---|
Market Cap | $16.82B | $1.06B |
Volume | 223,093 | 2,402,888 |
Sector | Health | Income / Options Overlay |
52-Week High | $630.19 | $67.85 |
52-Week Low | $393.42 | $11.55 |
Typical Hold Time | 14 Days | 30 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
MSTY trades at $15.83, down 5.61% today amid bearish technical signals. The ETF shows mixed sentiment with Seeking Alpha rating it Hold despite a 100.32% annualized distribution rate. Recent articles highlight significant NAV erosion, with $10,000 investments declining to approximately $6,614 over six months according to 24/7 Wall Street analysis from July 2026.
The fund's high distribution strategy comes with substantial principal erosion risk. While weekly dividends provide income, the structural design returns investor capital as distributions. Analyst consensus remains cautious due to the fund's dependence on MSTR volatility and ongoing NAV decline, making this suitable only for sophisticated investors understanding the income-principal tradeoff.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
